FeesSafety
Pluang+

Investigation launched into Integra LifeSciences over delayed flood impact disclosures.

Market News
04 Oct 2026, 17:29 WIB
Newsfile Corp
View Source
Bearish
Investigation launched into Integra LifeSciences over delayed flood impact disclosures.

Johnson Fistel, PLLP is investigating Integra LifeSciences for potentially failing to disclose the full impact of flooding at its Cincinnati manufacturing facility. Integra initially downplayed the flooding's effect on its 2026 revenue and earnings guidance, but later revealed $7 million in lost third-quarter revenue and an expected $15-20 million impact in the fourth quarter. The company also delayed full operational recovery until mid-2027 and lowered its revenue and earnings forecasts, causing shares to drop over 21%. The investigation will determine if Integra's management misled investors about the disruption's severity and timeline.

Integra LifeSciences faces an investor investigation following flooding-related outlook cuts and a 21% stock decline. For readers following the health sector, here is Pluang's market snapshot as of Oct 04, 2026 20:41 WIB: out of 100 priced health-sector US stocks tradable on Pluang, 49 rose and 48 fell today. Notable movers include AXGN (Axogen Inc) at USD 37.39 with a 1-day change of -6.34% and 100% buy order activity, TXG (10X Genomics Inc) at USD 93.50 with +5.34% change and 93% buy order activity, and ALNY (Alnylam Pharmaceuticals, Inc.) at USD 219.72 with -4.96% change.

More News

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...

Company Fundamentals
Bullish
38 minutes ago
EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

EU approves Sanofi's new-generation rabies vaccine VaxRabeo for all ages

Sanofi's new rabies vaccine, VaxRabeo, has been approved by the European Commission for use in all age groups for both pre-exposure and post-exposure prophylaxis. The vaccine, made with advanced Vero cell technology, offers longer shelf life and bett...

Market News
Bullish
38 minutes ago
GQG Partners lists its first actively managed US equity ETF on Abu Dhabi Securities Exchange

GQG Partners lists its first actively managed US equity ETF on Abu Dhabi Securities Exchange

GQG Partners has listed its first actively managed US equity ETF, GQG US Equity ETF (GQGU), on the Abu Dhabi Securities Exchange (ADX). This marks GQG's first ETF listing outside the US, expanding regional investor access to its US stock investment s...

Company Fundamentals
Bullish
38 minutes ago
gategroup provides specialized inflight catering for Pope Leo XIV's historic South America trip

gategroup provides specialized inflight catering for Pope Leo XIV's historic South America trip

gategroup, a global leader in airline catering, supplied specialized onboard catering and logistical support for Pope Leo XIV's apostolic journey across South America. Collaborating with ITA Airways, Aerolíneas Argentinas, and LATAM Airlines, gategro...

Bullish
38 minutes ago
GRAIL nears FDA approval for Galleri cancer test, boosting market potential and scaling costs.

GRAIL nears FDA approval for Galleri cancer test, boosting market potential and scaling costs.

GRAIL reported strong growth in its Galleri multi-cancer early detection test, completing over 174,000 tests in nine months of 2026 and seeing a 24% volume increase in Q3. A positive FDA advisory vote positions Galleri to become the first FDA-approve...

Company Fundamentals
Bullish
45 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App